Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Cited In for PubMed (Select 18501052)

1.

Prognostic factors in acute methadone toxicity: a 5-year study.

Aghabiklooei A, Edalatparvar M, Zamani N, Mostafazadeh B.

J Toxicol. 2014;2014:341826. doi: 10.1155/2014/341826. Epub 2014 Aug 12.

2.

False sense of safety by daily QTc interval monitoring during methadone IVPCA titration in a patient with chronic pain.

Miranda-Grajales H, Hao J, Cruciani RA.

J Pain Res. 2013 May 20;6:375-8. doi: 10.2147/JPR.S42487. Print 2013.

3.

Pharmacogenomic considerations in opioid analgesia.

Vuilleumier PH, Stamer UM, Landau R.

Pharmgenomics Pers Med. 2012;5:73-87. doi: 10.2147/PGPM.S23422. Epub 2012 Aug 23. Erratum in: Pharmgenomics Pers Med. 2013;6:1.

4.

Applying legal risk management to the clinical use of methadone.

O'Donnell J, Vogenberg FR.

P T. 2011 Dec;36(12):813-22. No abstract available.

6.

Methadone use in children and young adults at a cancer center: a retrospective study.

Anghelescu DL, Faughnan LG, Hankins GM, Ward DA, Oakes LL.

J Opioid Manag. 2011 Sep-Oct;7(5):353-61.

7.

Methadone deaths in pain and addiction populations.

Grant KJ, Baca CT.

J Gen Intern Med. 2010 Sep;25(9):898; author reply 899. doi: 10.1007/s11606-010-1411-0. No abstract available.

8.

Methadone deaths: risk factors in pain and addicted populations.

Modesto-Lowe V, Brooks D, Petry N.

J Gen Intern Med. 2010 Apr;25(4):305-9. doi: 10.1007/s11606-009-1225-0. Epub 2010 Jan 20. Review.

9.

Methadone initiation and rotation in the outpatient setting for patients with cancer pain.

Parsons HA, de la Cruz M, El Osta B, Li Z, Calderon B, Palmer JL, Bruera E.

Cancer. 2010 Jan 15;116(2):520-8. doi: 10.1002/cncr.24754.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk